When the monkeypox outbreak began in May 2022, most impacted people started a search for a preventive vaccine. In the U.S., the government began offering vaccinations in Boston, then in New York and Washington DC.
But without peer-reviewed clinical studies, vaccine efficacy remained in question.
A recent study published by the journal Nature Medicine found the antibody response to the two-dose JYNNEOS® (MVA-BN) vaccine in non-primed people or those who had not previously received a smallpox vaccine was very low.
Read More
